The shareholder cash-out maze of Luoxin Pharmaceutical: Secret clauses suspected of false statements, the "De Yi system" faces repeated setbacks in exiting
A previously unseen Clause 8.3 of the "Share Transfer Agreement" has pushed Luoxin Pharmaceutical into the eye of the storm regarding capital operation compliance. The "De Yi System," which was deeply involved in Luoxin Pharmaceutical's backdoor listing, abruptly terminated the planned equity transfer after nearly six months of preparation, and the important contractual terms affecting the termination of this transaction were never disclosed, with securities lawyers pointing out that this move is suspected of false representation. Prior to this, Luoxin Pharmaceutical had a history of incomplete information disclosure